ABSTRACT BACKGROUND Exosomes are nanometer-sized vesicles released from cells into the blood, where they can transmit
which are present in the blood of humans and rodents in the order of 10 10 exosomes/ml (7).
These striking numbers raise crucial questions as to their role.
Coronary artery obstruction produces myocardial ischemia, which is usually treated with myocardial reperfusion, although this paradoxically causes further lethal injury that currently lacks an effective clinical therapy (8) . Heat shock proteins (HSPs) are powerfully cardioprotective (9) (10) (11) , but clinical translation faltered without practical techniques for their induction or delivery. After myocardial infarction, large elevations in serum HSP70
can stimulate inflammatory cytokine release via tolllike receptor (TLR) 4 and the innate immune response (12, 13) . However, a more mild stimulation of innate immunity via TLR ligands is necessary for myocardial pre-conditioning and cardioprotection (14, 15) .
This raises the possibility that delivery of moderate levels of HSP70 could be beneficial. In addition to these effects of circulating HSP70, other families of HSP can mediate protection within the cell. For example, the small HSP27 (HSPB1) is required for optimal protection against ischemia and reperfusion injury (16, 17) .
We hypothesized that endogenous exosomes communicate signals to the heart to protect it against ischemia and reperfusion injury. Furthermore, because recent evidence suggests that microvesicles can transfer protection by remote ischemic preconditioning (RIC) (18) , we hypothesized that RIC would augment exosome production, thereby stimulating cardioprotection. We purified, characterized, and quantified exosomes from the plasma of rats and humans, demonstrating protection against ischemia and reperfusion both in vitro and in vivo. was considered significant.
Additional details of the materials and methods are provided in the Online Appendix.
RESULTS
The exosome-rich fraction was purified from the blood of adult male rats and healthy human male volunteers using a standard protocol of serial, differential centrifugation, and ultracentrifugation steps. Using transmission electron microscopy (TEM),
we observed the typical "cup-shaped" vesicles of exosomes that were <100 nm in diameter for both rats and humans ( Figure 1A ).
We used nanoparticle tracking analysis to measure the number and size distribution of particles in purified, exosome-rich preparations; the modal size of particles purified from control rat plasma was 75 AE 2 nm ( Figures 1B and 1D ), corresponding to the exosomes' expected size, and the concentration was 0.1 AE 0.02 Â 10 11 ml À1 plasma (n ¼ 5 rats) ( Figure 1C) . In human plasma, particle concentration was 6 AE 3 Â 10 11 ml À1 (n ¼ 6) ( Figure 1C) , and average modal size was 75 AE 7 nm ( Figure 1D ). For simplicity, we refer hereafter to the isolated particles as "exosomes,"
although the isolated fraction also included some particles outside of the expected exosome size range.
Flow cytometry confirmed the expression of marker proteins for exosomes in the human samples.
The tetraspanin molecules CD63 and CD81 (found in many exosomes), as well as HSP70, were all detectable at high levels ( Figure 1E ). Isotype control antibodies were negative (Online Figure 1) . Interestingly, the positive signal obtained using antibody clone cmHSP70.1, which specifically recognizes an epitope of HSP70 expressed on the surface of cells and exosomes (19, 20) , suggested that HSP70 is exposed on the surface of human exosomes ( Figure 1E ).
We also performed sodium dodecyl sulfatepolyacrylamide gel electrophoresis and Western blot Plasma Exosomes and Cardioprotection analyses to biochemically characterize the human samples and were able to detect CD63, CD81, and HSP70 ( Figure 1F ). Similar results were obtained using rat exosomes (Online Figure 2 ).
To investigate whether plasma exosomes are cardioprotective, we used 4 different experimental models. In an in vivo rat model, the entire exosome fraction isolated from a donor rat was administered to a naïve rat by intravenous tail vein injection 15 min before occlusion of the left anterior descending artery. The area at risk was the same in each group (Online Figure 3A) . The infarct size relative to the area at risk was reduced from 48 AE 5% (n ¼ 6) with vehicle to 25 AE 6% (p < 0.05; n ¼ 6) with exosomes ( Figure 2A) . Second, to exclude the influence of blood, Langendorff-perfused rat hearts were exposed to all of the exosomes isolated from donor rat blood during 15-min perfusion, before being subjected to 35-min ischemia followed by 2-h reperfusion. The area at risk was the same in each group (Online Figure 3B ). The size of the infarct relative to the area at risk was significantly reduced from 35 AE 3% (n ¼ 6) to 22 AE 2% (p < 0.01; n ¼ 10) by pre-treatment with rat exosomes ( Figure 2B ). The maximal tested dose of 10 9 exosomes/well was highly cardioprotective, reducing cell death to 17 AE 3%, which is similar to the effect of insulin (14 AE 3%), and this protection remained down to a dose of 10 7 exosomes/well, at which exosomes decreased death to 32 AE 8% ( Figure 2D ).
If exosomes can activate cardioprotective pathways, this raises the possibility that manipulating their levels in the blood might affect cardioprotection. No specific pharmacological inhibitors have yet been developed for in vivo use to decrease exosome production. However, it has recently been proposed that brief cycles of hind limb ischemia and reperfusion increase the number of extracellular vesicles (both exosomes and microvesicles) in the circulation (18) . Such RIC also renders the heart in a protected state (21, 22) .
We first looked for any effect on plasma exosomes in humans subject to RIC. Exosomes were isolated from healthy volunteers both before and after a standard RIC procedure and were characterized by nanoparticle tracking analysis and TEM. RIC exosomes exhibited the same size and shape as control exosomes ( Figures 1G to 1J ), but importantly, their concentration in plasma was significantly increased after RIC ( Figure 1H ). Exosome concentration was similarly increased in rats after RIC (Online Figure 4A ).
The ability of exosomes from RIC-treated rats to protect the heart was then determined. Administration of RIC exosomes significantly decreased infarct size, both in vivo ( Figure 2A ) and in vitro ( Figure 2B ).
We performed a complete dose-response curve comparing exosomes from control and RIC rats, using the in vitro model of hypoxia-reoxygenation on primary cardiomyocytes. Although RIC exosomes slightly increased protection, the difference was nonsignificant ( Figure 2D ). This suggested that Both drugs completely inhibited ERK1/2 phosphorylation in response to human exosomes ( Figure 3D) as well as eliminated cardioprotection in adult rat cardiomyocytes treated with human exosomes ( Figure 3E) . In control experiments, the inhibitors alone had no effect (Online Figure 6) . Plasma Exosomes and Cardioprotection Figure 4C) . Furthermore, these exosomes were no longer able to protect primary cardiomyocytes against hypoxia and reoxygenation, and by itself, the neutralizing antibody did not affect cell survival ( Figure 4D ).
Upstream of HSP27 phosphorylation, 1 of the most well-established activators is p38MAPK. Using SB203580, an inhibitor of p38MAPKa/b, we observed that HSP27 phosphorylation in response to exosomes was blocked, whereas upstream ERK1/2 phosphorylation remained unaffected ( Figure 5A ). As discussed earlier, U0126 blocked ERK1/2 phosphorylation, but also prevented phosphorylation of HSP27 ( Figure 5A ).
These results suggest that ERK1/2 lies upstream of p38MAPK in the pathway.
To establish a link between extracellular HSP70
and intracellular ERK1/2 and p38MAPK activation, we used TAK-242 to block intracellular signaling from TLR4. Pre-treatment with TAK-242 decreased ERK1/2 phosphorylation in response to exosomes and blocked HSP27 phosphorylation ( Figure 5A ).
Finally, we studied the effect of the whole pathway on the survival of cardiomyocytes subject to hypoxiareoxygenation. Blocking TLR4, ERK1/2, or p38MAPK decreased the cardioprotective effect of exosome treatment ( Figure 5B) . SB203580 is specific to a and b isoforms of p38MAPK, which are also the 2 isoforms that are protective when transiently activated before ischemia (28) .
One of the most well-characterized members of the cardioprotective, small HSP family, HSP27 is highly expressed in the myocardium (16) . In addition to controlling protein folding, small HSPs exert powerful protection against oxidative stress and apoptosis and maintain sarcomeric structure (16, 17) .
Strikingly, despite being well-characterized and strongly activated in response to heat stress, no practical method of stimulating HSP27 phosphorylation has been developed and translated to the clinic.
Our study shows for the first time to our knowledge that endogenous plasma exosomes can activate this HSP.
We previously developed a neutralizing antibody against the highly-conserved, exposed C-terminal of HSP70 (19) , demonstrating that it blocks the immunosuppressive signaling pathways stimulated by exosomal HSP70 in myeloid-derived suppressor cells (20) . We show here that neutralizing HSP70 on exosomes prevents their protective actions in cardiomyocytes. Heat shock proteins, including HSP27
and HSP70, are intracellular chaperones important for Plasma Exosomes and Cardioprotection correct protein homeostasis. HSP70 is secreted from cells by exosomes (20) and is present in the serum of healthy individuals (29) . Beyond HSP70's wellestablished intracellular protective role, an intriguing new, extracellular role is emerging for HSP70 (30) .
For instance, supporting cells in the inner ear can secrete HSP70 to protect hair cells from cell death in response to ototoxic drugs (31) . Plasma HSP70 is believed to play a role in activating the adaptive and innate immune response (32) . Although activating the innate immune system is generally considered to be detrimental to the heart, a small degree of activation is protective (15); this is highly reminiscent of the manner in which sublethal episodes of ischemia are protective during ischemic pre-conditioning.
Importantly, mice lacking TLR4 appear resistant to the beneficial effects of pre-conditioning (14, 15) .
Our data suggest that exosomal HSP70 can activate protective pathways in cardiomyocytes via TLR4, part of the ancient, innate immune system response.
STUDY LIMITATIONS. It is not currently possible to achieve complete purity of exosomes from plasma, and consequently, significant amount of proteins and
CENTRAL ILLUSTRATION Exosome-Stimulated Cardioprotection
The proposed mechanism of action by which exosomes communicate cardioprotective signals to the heart is mediated by heat shock protein (HSP) 70 on exosomes. This activates a pathway downstream of toll-like receptor 4 (TLR) involving extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) and p38 mitogen-activated protein kinase (p38MAPK), leading to phosphorylation of HSP27.
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